What is Dendreon?
Founded in 1992 and headquartered in Seal Beach, California, Dendreon operates within the biotechnology sector, focusing on the development and manufacturing of immune-therapeutics designed for cancer treatments. The company's specialization in novel therapeutic approaches positions it within a critical area of medical innovation, aiming to leverage the body's own immune system to combat malignant diseases. Its long-standing presence in the industry suggests a deep-rooted commitment to advancing oncology care through scientific research and development.
How much funding has Dendreon raised?
Dendreon has raised a total of $50M across 2 funding rounds:
Stock Offering
$45M
Debt
$5M
Stock Issuance/Offering (2000): $45M, investors not publicly disclosed
Debt (2020): $5M led by PPP
Key Investors in Dendreon
PPP
Public-Private Partnership
What's next for Dendreon?
With a significant enterprise-level funding context and a recent strategic investment, Dendreon is poised for potential expansion and further research into its immune-therapeutic pipeline. The company's trajectory suggests a focus on scaling its manufacturing capabilities and advancing its clinical trials. Future developments will likely center on bringing its innovative cancer treatments to a broader patient population, navigating regulatory pathways, and potentially forging new partnerships within the pharmaceutical and healthcare industries to accelerate its growth and market penetration.
See full Dendreon company page
